Standard BioTools(US:LAB) Newsfilter·2024-07-17 12:01Core Viewpoint - Standard BioTools Inc. will report its second quarter 2024 financial results on July 31, 2024, after market close, followed by a conference call to discuss these results and operational progress [1][2]. Company Overview - Standard BioTools Inc. (Nasdaq: LAB), formerly known as Fluidigm Corporation, specializes in next-generation technologies that aid biomedical researchers in developing medicines more efficiently [4]. - The company offers proprietary mass cytometry and microfluidics technologies, providing reliable insights in health and disease, which contribute to improved patient outcomes [4]. - Standard BioTools collaborates with various sectors, including academic, government, pharmaceutical, biotechnology, and clinical laboratories, focusing on critical areas in translational and clinical research such as oncology and immunology [4].